Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?
New study findings provide support for the use of ctDNA to predict survival benefits and personalise treatments
Reshaping the treatment landscape for GI cancers
ADCs are transforming the management of patients with GI cancers, but novel targets and combination strategies will be required to address resistance development and optimise patient outcomes
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance